论文部分内容阅读
Siva1是凋亡诱导因子Siva编码的一种选择性剪接体,其不仅可以与多种受体如CD27、Bcl-2或Bcl-xL、c-Abl、LPA2结合而发生相互作用,并通过调控ARF-MDM2-p53通路、抑制NF-κB的活性和酪氨酸磷酸化等方式促进细胞的凋亡,而且还可以通过抑制微管解聚蛋白Stathmin的活性和稳定微管来抑制上皮-间质细胞转化和肿瘤细胞转移。此外,Siva1可作为肿瘤患者顺铂化疗的增效剂。当今,恶性肿瘤已严重危害人类健康,其发病人数正逐年增加,故对Siva1分子机制的深入研究,必将为肿瘤的靶向治疗提供新的思路和广阔的应用前景。因此,本文就目前Siva1在国内外的相关研究进展作一综述。
Siva1 is an alternative spliceosome encoded by Siva, an apoptosis-inducing factor that not only binds to a variety of receptors such as CD27, Bcl-2 or Bcl-xL, c-Abl and LPA2 but also interacts by modulating ARF -MDM2-p53 pathway, inhibit the activity of NF-κB and tyrosine phosphorylation, but also can inhibit epithelial-mesenchymal cells by inhibiting the activity of microtubule-deregulated Stathmin and stabilizing microtubules Transformation and tumor cell metastasis. In addition, Siva1 can be used as a synergist for cisplatin chemotherapy in cancer patients. Nowadays, malignant tumors have seriously endanger human health and the number of their occurrence is increasing year by year. Therefore, in-depth study on the molecular mechanism of Siva1 will certainly provide new ideas and broad application prospects for the targeted therapy of tumors. Therefore, this article reviews the current research progress of Siva1 at home and abroad.